Budget Impact Analysis of Delgocitinib Cream for Moderate to Severe Chronic Hand Eczema in the United States
Main Article Content
Keywords
Budget impact, delgocitinib, Chronic Hand Eczema
References
2. Thyssen et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis.
2022;86(5):357-378.
3. Bewley et al. The psychosocial impact of chronic hand eczema - findings from the population-based CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden) study. Presented at: ISPOR Europe; November 2024.
4. Fowler et al. Impact of chronic hand dermatitis on quality of life,
work productivity, activity impairment, and medical costs. Journal of the American Academy of Dermatology. 2006;54(3):448-457.
5. Armstrong et al. Economic Burden of Chronic Hand Eczema: A Review. Am J Clin Dermatol. 2022;23(3):287-300.
6. Augustin et al. Cost‐of‐illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. British Journal of Dermatology. 2011;165(4):845-851.
7. Molin et al. Health care visits and out-of-pocket costs in people with Chronic Hand Eczema. Presented at: ISPOR; November 2024.
8. FDA. Anzupgo® Prescribing Information. 2025. Accessed August 10 2025.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219155s000lbl.pdf
9. OECD. Consumer price index (CPI). 2025. Accessed August 10 2025. https://stats.oecd.org/index.aspx?DataSetCode=PRICES_CPI#
10. LEO pharma. US CHECK study. Data on File. 2025.
11. Quaade et al. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84(6):361-374.
12. Apfelbacher et al. Chronic hand eczema in Germany: 5‐year follow‐up data from the CARPE registry. Contact Dermatitis. 2019;80(1):45-53.
13. Crane et al. Hand eczema and steroid-refractory chronic hand
eczema in general practice: prevalence and initial treatment. Br J Dermatol. 2017;176(4):955-964.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.